News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Alberto Hernando-Calvo: Durvalumab with Olaparib or Cediranib in patients with pMMR CRC or Pancreatic Cancer
Photo taken from Alberto Hernando-Calvo/X
Jul 11, 2024, 10:49

Alberto Hernando-Calvo: Durvalumab with Olaparib or Cediranib in patients with pMMR CRC or Pancreatic Cancer

Alberto Hernando-Calvo, Clinician scientist at Vall d’Hebron Barcelona Hospital, shared on X:

“Phase II, open-label, randomized trial of durvalumab with olaparib or cediranib in patients with proficient mismatch repair (pMMR) Colorectal Cancer (CRC) or pancreatic cancer at Princess Margaret Cancer Centre. Mentorship from Aaron Hansen and Lillian Siu and support from Pugh Lab, Benjamin Haibe-Kains labs, Ontario Institute for Cancer Research and others!”

A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer

Authors: Alberto Hernando-Calvo, Ming Han, Olubukola Ayodele, Ben X. Wang, Jeffrey P. Bruce, Farnoosh Abbas-Aghababazadeh, Maria Vila-Casadesús, Enrique Sanz-Garcia, S.Y. Cindy Yang, Hal K. Berman, Ana Vivancos, Bernard Lam, Ilinca Lungu, Abdulazeez Salawu, Lee-Anne Stayner, Benjamin Haibe-Kains, Philippe L. Bedard, Lisa Avery, Albiruni R.A. Razak, Trevor J. Pugh, Anna Spreafico, Lillian L. Siu, Aaron R. Hansen.

Alberto Hernando-Calvo: Durvalumab with Olaparib or Cediranib in patients with pMMR CRC or Pancreatic Cancer

Source: Alberto Hernando-Calvo/X

Aaron Hansen Aaron R. Hansen Abdulazeez Salawu Alberto Hernando Calvo Albiruni R.A. Razak Ana Vivancos Anna Spreafico Ben X. Wang Benjamin Haibe-Kains Benjamin Haibe-Kains labs Bernard Lam cancer cediranib colorectal cancer CRC Durvalumab Enrique Sanz-Garcia Farnoosh Abbas-Aghababazadeh Hal K. Berman Ilinca Lungu Jeffrey P. Bruce Lee-Anne Stayner Lillian L. Siu Lisa Avery Maria Vila-Casadesús Ming Han olaparib Olubukola Ayodele OncoDaily Oncology Ontario Institute for Cancer Research Pancreatic Cancer Philippe L. Bedard Princess Margaret Cancer Centre Pugh Lab S.Y. Cindy Yang Trevor J. Pugh Vall d'Hebron Barcelona Hospital
Special Coverage
Blog
Dec 21, 2024, 14:10
Arif Kamal: Ensuring all people have access to the cancer navigation services that will help them live more and better days
Blog
Dec 21, 2024, 14:06
The Accelerate 2025 Annual Conference Agenda Is Here!
Blog
Dec 21, 2024, 14:03
Pioneer the future of discovery and innovation with a fully funded Bicentenary PhD Studentship at The University of Manchester
Blog
Dec 21, 2024, 14:00
NCI Division of Cancer Prevention - DHT Derived Biomarkers and COAs for Remote Monitoring and Endpoint Development
Blog
Dec 21, 2024, 13:51
The ESMO President Letter emphasises the importance of collective action to shape the future of oncology
Blog
Dec 21, 2024, 13:48
Overcoming recurrence: How research is bringing new hope for breast cancer patients - The Institute of Cancer Research
Blog
Dec 21, 2024, 13:46
IARC - Cancer Incidence in Five Continents, Vol XII
Blog
Dec 21, 2024, 13:43
National University Cancer Institute, Singapore clinicians had the exciting opportunity to present their work at the ESMO Asia 2024
Blog
Dec 21, 2024, 13:40
UICC - Welcoming the newest member, The World Hepatitis Alliance
Blog
Dec 21, 2024, 13:35
Pediatric Cancer and Blood Disorders Center of Armenia - Prioritizing the continuous education and knowledge exchange of the medical staff
Blog
Dec 21, 2024, 13:33
SIOP Europe - International Childhood Cancer Day 2025
Blog
Dec 21, 2024, 13:29
Canadian Cancer Society - How 5 organizations are working to take on cancer’s biggest issues